SphingoTec develops innovative biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions.
Sphingotec GmbH has raised $5.5M in total funding. The most recent round was Series C. The last funding was announced in August 2024.
Sphingotec GmbH's investors include Wellington Partners, NRW.BANK, Brandenburg Kapital, HBM Partners, HBM Healthcare Investments.
Sphingotec GmbH is headquartered in Hohen Neuendorf, Germany.
SphingoTec develops innovative biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions.
Sphingotec GmbH is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Sphingotec GmbH — Funding & Investors." VCBacked, August 8, 2024, https://www.vcbacked.co/company/sphingotec-gmbh. Accessed November 14, 2026.
VCBacked. (2024). Sphingotec GmbH — Funding & Investors. Retrieved November 14, 2026, from https://www.vcbacked.co/company/sphingotec-gmbh
{{cite web |title=Sphingotec GmbH — Funding & Investors |url=https://www.vcbacked.co/company/sphingotec-gmbh |website=VCBacked |access-date=November 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Sphingotec GmbH? Request a listing update